GORNOSLASKIE CENTRUM MEDYCZNE IM. PROF. LESZKA GIECA SLASKIEGO UNIWERSYTETU MEDYCZNEGO W KATOWICACH

Their core work

GCM is a major clinical hospital affiliated with the Medical University of Silesia in Katowice, Poland, specializing in advanced cardiovascular care. The center serves as a clinical trial site for European research projects investigating new therapies for severe heart conditions — from stem cell and gene therapies for ischemic heart disease to stereotactic radiotherapy for life-threatening cardiac arrhythmias. Their real-world value lies in providing patient access, clinical infrastructure, and cardiology expertise needed to validate experimental treatments in real hospital settings.

What they specialise in

How they've shifted over time

GCM's earlier involvement (2015-2020) centered on biological regenerative approaches — stem cell therapy and gene therapy for ischemic heart disease and angina. Their most recent project (STOPSTORM, 2021) marks a shift toward radiation-based cardiac intervention, specifically stereotactic body radiotherapy for ventricular tachycardia. This evolution mirrors a broader cardiology trend from regenerative biology toward precision radiation techniques for arrhythmia management.

GCM is moving from biological regeneration (stem cells, gene therapy) toward non-invasive radiation-based cardiac interventions, positioning them at the intersection of cardiology and radiation oncology.

How they like to work

GCM operates primarily as a third-party clinical site rather than a project driver — two of three projects list them as a third party, and they have never coordinated an H2020 project. They join large, multi-country consortia (44 unique partners across 13 countries), which is typical for a hospital contributing patient cohorts and clinical trial capacity. This means they are low-overhead partners: they bring patients and clinical expertise without demanding project leadership responsibilities.

GCM has worked with 44 distinct consortium partners across 13 countries, indicating broad European connectivity in the cardiovascular clinical trial space despite their limited number of projects.

What sets them apart

GCM combines a large clinical cardiology department with university-level research capacity, making it a reliable clinical trial site in Central-Eastern Europe. Their progression from stem cell and gene therapy trials to cardiac radioablation shows they stay at the frontier of experimental cardiac treatments. For consortium builders, they offer access to a Polish patient population and clinical infrastructure — an underrepresented geography in many Western-European-led cardiac trials.

Highlights from their portfolio

• STOPSTORM
  Their only project as a direct participant (not third party), and their most recent — a prospective European validation cohort for stereotactic treatment of cardiac arrhythmias, running until 2027.
• ReGenHeart
  Clinical proof-of-principle testing of VEGF-D gene therapy for angina — a regenerative medicine approach to cardiovascular disease that bridges gene therapy and cardiology.